FGF2 and head and neck squamous cell carcinoma: Additionally, increased FGF2 expression in bevacizumab-resistant HNSCC cells, accompanied with upregulation of PLCγ, ERKs, and AKT, correlated with the reduced sensitivity to the bevacizumab treatment [53].